BMS, Gilead to make cancer drug combo; SAFC plant certified for high potency APIs;

> Bristol-Myers Squibb ($BMY) and Gilead Sciences ($GILD) have joined forces to develop and manufacture a fixed-dose combination of BMS's protease inhibitor Reyataz and Gilead's booster drug, Cobicistat. Release

> Sigma-Aldrich ($SIAL) unit SAFC has earned SafeBridge Certification for its commercial-scale high-potency API facility in Verona, WI. Announcement

> Logistics challenges in the Indian market include lack of infrastructure and skilled labor, maintaining the quality of goods during transit and a "crippling" lack of multimodal transport solutions. Story

> Process automation specialist Endress+Hauser has acquired a stake in Finesse Solutions, maker of sensors, hardware and software for bioprocess engineering. Release

> The U.K. Department of Health has renewed its long-term contract with Movianto for storage and distribution of childhood vaccines. Announcement

> PharmaSecure has won a $3.9 million investment from several venture firms to create new applications for India's drug serialization requirements that go into effect next year. News

> Israeli police have seized more than 30 packages of counterfeit diet pills, which contain the active ingredients in the anti-depressant Prozac, Valium and an amphetamine. Item

> CMC Biologics will provide manufacturing and process development services to Daiichi Sankyo for clinical-stage antibodies. Release

Suggested Articles

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.